The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants
Michael G. Heckman, Alexis Elbaz, Alexandra I. Soto‐Ortolaza, Daniel Serie, Jan Aasly, Grazia Annesi, Georg Auburger, Justin A. Bacon, Magdalena Boczarska‐Jedynak, Maria Bozi, Laura Brighina, Marie‐Christine Chartier‐Harlin, Efthimios Dardiotis, A. Destée, Carlo Ferrarese, Alessandro Ferraris, Brian Fiske, Suzana Gispert, Georgios M. Hadjigeorgiou, Nobutaka Hattori, John P A Ioannidis, Barbara Jasińska‐Myga, Beom S. Jeon, Yun Joong Kim, Christine Klein, Rejko Krüger, Elli Kyratzi, Chin‐Hsien Lin, Katja Lohmann, Marie‐Anne Loriot, Timothy Lynch, George D. Mellick, Eugénie Mutez, Grzegorz Opala, Sung Sup Park, Simona Petrucci, Aldo Quattrone, Manu Sharma, Peter A. Silburn, Young H. Sohn, Leonidas Stefanis, Vera Tadić, Hiroyuki Tomiyama, Ryan J. Uitti, Enza Maria Valente, Demetrios K. Vassilatis, Carles Vilariño‐Güell, Linda R. White, Karin Wirdefeldt, Zbigniew K. Wszołek, Ruey‐Meei Wu, Georgia Xiromerisiou, Demetrius M. Maraganore, Matthew J. Farrer, Owen A. Ross (2013). The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. , 35(1), DOI: https://doi.org/10.1016/j.neurobiolaging.2013.07.013.
